THORENOOR, Nithyananda, Petra VYCHYTILOVÁ, Jitka MLČOCHOVÁ, Sonja HOMBACH, Markus KRETZ, Jiří ŠÁNA and Ondřej SLABÝ. ZFAS1, long non-coding RNA with significance in colorectal cancer. In 106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia. 2015. ISSN 0008-5472.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name ZFAS1, long non-coding RNA with significance in colorectal cancer
Authors THORENOOR, Nithyananda, Petra VYCHYTILOVÁ, Jitka MLČOCHOVÁ, Sonja HOMBACH, Markus KRETZ, Jiří ŠÁNA and Ondřej SLABÝ.
Edition 106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia, 2015.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 8.556
Organization unit Central European Institute of Technology
ISSN 0008-5472
Keywords in English lncRNAs; ZFAS1; colorectal cancer
Tags International impact, Reviewed
Changed by Changed by: Mgr. Petra Vychytilová, Ph.D., učo 211789. Changed: 2/9/2016 11:34.
Abstract
Introduction: Colorectal cancer (CRC) is one of the most common cancers in the world. However, the existence of multiple known carcinogens and varying genetic backgrounds makes it difficult to determine which factors are most important in the development of CRC. Therefore, the identification of a bona fide molecule involved in progression of CRC has been greatly sought after. Long noncoding RNAs (lncRNA) are emerging as key molecules in human cancer, and some of them were shown to have potential for cancer diagnosis and prognosis. ZFAS1, an lncRNA, has been recently revealed involving in human breast cancer as putative tumor suppressor. However, whether ZFAS1 is involved in CRC pathogenesis or could serve as novel biomarker in CRC is unknown. Patients and methods: By use of high throughput technology we identified ZFAS1 as one of the highly up-regulated lncRNA in CRC tissue. Thus, aim of the current study was to explore the correlation between ZFAS1 expression and progression of CRC and its clinical significance. The expression levels of ZFAS1 were determined by quantitative real-time PCR and in selected cases by Northern blot and evaluated in larger cohort (120 cases) of CRC tissues and cell lines (HCT116, DLD1, SW620), which were compared to paired adjacent normal tissues or normal colonic cell lines. The potential relationship between ZFAS1 levels in tumor tissues and the clinicopathological features of CRC was also evaluated. Further, we assessed whether ZFAS1 influences cell proliferation, apoptosis, cell cycle and migration in-vitro. The different isoforms of ZFAS1 were determined by RACE-PCR and protein interacting partners of ZFAS1 were analyzed by pull-down experiment and mass spectrometry. The identified candidate proteins were evaluated by RNA-IP. Results: Our results showed that ZFAS1 expression in CRC tissues and cell lines were significantly increased compared with matched normal tissues (p < 0.0001). In addition, siRNA-mediated knockdown of ZFAS1 expression significantly influenced the proliferation of CRC cells (p < 0.05) Interestingly, ZFAS1 intronically hosts three C/D box snoRNAs (SNORDs): SNORD12, 12B, and 12B. The general assumption that noncoding SNORD-host transcripts function only as vehicles to generate snoRNAs, knockdown of ZFAS1 in a CRC cell lines resulted in decreased cellular proliferation, while not substantially altering the levels of the SNORDs. Conclusion: Our current study demonstrates that ZFAS1 levels are increased in CRC tissue and influences significantly proliferation of CRC cells in vitro, indicating its potential oncogenic functioning in CRC.
Links
EE2.3.30.0037, research and development projectName: Zaměstnáním nejlepších mladých vědců k rozvoji mezinárodní spolupráce
NT13549, research and development projectName: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem
NT13860, research and development projectName: Studium signální dráhy EGFR a expresních profilů mikroRNA v predikci odpovědi na cílenou anti-EGFR terapii u pacientů s kolorektálním karcinomem s nemutovanou variantou onkogenu KRAS
PrintDisplayed: 29/5/2024 19:59